News zu VIFOR PHARMA

Tavneos® erhält Swissmedic-Zulassung für die Behandlung ANCA-assoziierter Vaskulitis · Uhr · Business Wire
Update zum Zeitplan des öffentlichen Kaufangebots für Vifor Pharma · Uhr · Business Wire
Update on the timeline for Vifor Pharma tender offer · Uhr · Business Wire
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent · Uhr · Business Wire
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar · Uhr · Business Wire
Kapruvia® receives positive CHMP opinion for the treatment of moderate-to-severe pruritus in hemodialysis patients · Uhr · Business Wire
Vifor Pharma Gruppe erzielt nachhaltiges Wachstum in 2021 · Uhr · Business Wire
Vifor Pharma reports sustained growth in 2021 · Uhr · Business Wire
Vifor Pharma gibt Markteinführung von Tavneos® in Deutschland bekannt · Uhr · Business Wire
Vifor Pharma appoints two new members to the Executive Committee · Uhr · Business Wire
VFMCRP receives EU approval for Tavneos® for the treatment of ANCA-associated vasculitis · Uhr · Business Wire
CSL Behring AG publishes Offer Prospectus on public tender offer for all publicly held shares of Vifor Pharma Ltd. · Uhr · Business Wire
Vifor Pharma reports positive outcome of the phase-IIIb DIAMOND trial of Veltassa® · Uhr · Business Wire
Vifor Pharma and American Regent announce settlement of Injectafer® patent litigation · Uhr · Business Wire
Vifor Pharma drives transformation with divestment of non-core finished drug manufacturing to CordenPharma · Uhr · Business Wire
Vifor Pharma nimmt Stellung zu Medienspekulationen · Uhr · Business Wire
Vifor Pharma comments on media speculation · Uhr · Business Wire
Vifor Pharma appoints Hervé Gisserot as new Chief Commercial Officer and member of the Executive Committee · Uhr · Business Wire
Vifor Pharma and Angion report topline results from phase-II GUARD trial of ANG-3777 in cardiac surgery associated acute kidney injury · Uhr · Business Wire
Vifor Pharma comments on market speculations · Uhr · Business Wire
Vifor Pharma announces changes to the Executive Committee as CFO retires · Uhr · Business Wire
Vifor Pharma to spearhead development of vascular calcification field, through acquisition of Sanifit Therapeutics and Inositec AG · Uhr · Business Wire
VFMCRP receives positive CHMP opinion for Tavneos® for the treatment of ANCA-associated vasculitis · Uhr · Business Wire
Vifor Pharma and Angion report topline results from phase-III registration trial of ANG-3777 in kidney transplant patients at risk for delayed graft function · Uhr · Business Wire